You are here

BrainStorm Issues a Statement to Patients and Shareholders

NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, in response to numerous requests, issues today the following statement:
Tuesday, February 19, 2019 - 08:06